Journal of Advanced Research in Biochemistry and Pharmacology
Volume 6, Print Issue 1 - 2023, Pg. No. 1-6
Peer Reviewed Journal

Review Article

A Review of Recent Developments in Cardiovascular Pharmacology and Their Relevance to Patient Care

Jyoti Mishra

Student, Department of chemistry, Mamata Medical College, Rotary Nagar, Telangana, India.

I N F O

E-mail Id:
mishrajyoti 42@gmail.com
Orcid Id:
https://orcid.org/0009-0000-4967- 8876

How to cite this article:
Mishra J. A Review of Recent Developments in Cardiovascular Pharmacology and Their Relevance to Patient Care. *J Adv Res Biochem Pharma* 2023; 6(1): 1-6.

Date of Submission: 2023-06-29
Date of Acceptance: 2023-07-30

A B S T R A C T

A major worldwide health issue, cardiovascular diseases (CVDs) cause significant morbidity and mortality. Cardiovascular pharmacology has made notable advancements in recent years, encouraging the creation of novel therapeutic molecules and improving our understanding of conventional therapies. This review article takes readers on a tour of current developments in cardiovascular pharmacology, highlighting key medication classes, their mechanisms of action, practical implications for patient care. The field of antihypertensive medications, antiplatelet pharmaceuticals, lipid-lowering strategies, novel pharmacotherapies targeting cardiac remodeling and arrhythmias are meticulously investigated. We also explore how personalized medicine and pharmacogenomics work together, illuminating how it has become essential to tailor therapeutic approaches to specific patients. This review highlights the crucial importance of evidence-based prescribing and the tailored customization of treatments by shining a spotlight on these cutting-edge developments, ultimately charting a path toward improved cardiovascular outcomes. This synthesis of recent development invites us to embrace a future in which patient treatment is painstakingly planned and the fight against CVDs is fought with ever-increasing precision as the scientific horizon of cardiovascular pharmacology broadens.

Keywords: Pharmacogenomics, Personalized Medicine, Cardiovascular Pharmacology, Challenges, Emerging Therapies, Future Directions

Introduction

Cardiovascular Diseases (CVDs), which include a variety of conditions that affect the heart and blood vessels, pose a serious threat to world health. The widespread impact of chronic illnesses on mortality, morbidity, quality of life has sparked an unceasing search for cutting-edge methods to treat them. The field of cardiovascular pharmacology has become a crucial frontier in this setting, serving as a cornerstone in the complex strategy for treating and avoiding consequences from CVD.[1]

Heart failure, arrhythmias, atherosclerosis, hypertension, coronary artery disease are just a few of the varied disorders that fall under the umbrella term of CVDs. Pharmaceutical interventions are well-known for being essential weapons in the arsenal against these illnesses. The landscape of cardiovascular pharmacology has undergone a profound transformation, from the historic introduction of beta-blockers and angiotensin-converting enzyme (ACE) inhibitors to contemporary breakthroughs, such as angiotensin receptor-neprilysin inhibitors (ARNIs) and direct oral anticoagulants (DOACs).[2]

The constant pursuit of deeper understandings into the complex interactions between molecular pathways, cellular signaling, physiological processes that underpin cardiovascular health and dysfunction is what drives these paradigm-shifting changes. As a result, the arsenal of pharmacotherapies has grown to include drugs with specific modes of action that not only treat symptoms but also target the pathophysiology at play. Modern cardiovascular pharmacology's paradigm change from symptom-centric to etiology-driven therapies is the best example of this.[3]

Additionally, recent developments have improved awareness of the individual heterogeneity in drug reactions in addition to creating new pharmacological classes. The development of pharmacogenomics and personalized medicine has made it possible to customize therapeutic regimens to each patient's specific genetic makeup, improving treatment success and reducing side effects.

In light of this, this review begins a thorough investigation of recent developments in cardiovascular pharmacology. We seek to offer a comprehensive view of the changing landscape by exploring the complex mechanisms of action, clinical consequences, new trends. The overall goal of this synthesis is to highlight the crucial role that pharmacology will play in determining the course of cardiovascular care in the future, providing optimism for better patient outcomes and a global decline in the burden of cardiovascular illnesses.[4]

Antiplatelet and Anticoagulant Therapies

Platelet activation and clot formation are the causes of myocardial infarction and stroke. Glycoprotein IIb/IIIa inhibitors and P2Y12 receptor inhibitors are two antiplatelet drugs that continue to be crucial in lowering thrombotic occurrences. Warfarin has been replaced by direct oral anticoagulants (DOACs), which have gained popularity because of their predictable pharmacokinetics and lower risk of bleeding.[5]

Antiplatelet and Anticoagulant Therapies: Navigating the Hemostatic Balance in Cardiovascular Care

Cardiovascular diseases (CVDs) frequently present as thrombotic episodes that upset the delicate hemostasis balance. Antiplatelet and anticoagulant medications are crucial in maintaining vascular integrity to prevent these potentially fatal events. This section explores how these medicines are developing, highlighting their mechanisms of action, clinical uses, the ongoing search for the best compromise between preventing clot formation and preventing consequences from bleeding.

Antiplatelet Therapies

Platelets are a key target for CVD prevention strategies because they are essential in the production of arterial thrombi. Traditional medications like aspirin prevent platelet aggregation by permanently inhibiting cyclooxygenase-1 (COX-1), a crucial enzyme in the production of thromboxane A2. Clopidogrel, prasugrel, ticagrelor are examples of P2Y12 receptor inhibitors that have recently been developed and which control ADP-induced platelet activation. The management of acute coronary syndromes and percutaneous coronary interventions has been completely transformed by the incorporation of these drugs into dual antiplatelet therapy (DAPT). A personalized regimen based on patient characteristics is required to balance bleeding risks with powerful antiplatelet effects.[6]

Anticoagulant Therapies

Anticoagulants target the coagulation cascade, a complex interaction of enzymes and factors, to stop venous and arterial thrombosis. Direct oral anticoagulants (DOACs), such as dabigatran, rivaroxaban, apixaban, edoxaban, have been added to traditional treatments like heparin and warfarin. In contrast to warfarin, these medications have predictable pharmacokinetics and fewer monitoring requirements by inhibiting particular coagulation components. The therapy of venous thromboembolism, deep vein thrombosis prophylaxis, stroke prevention in atrial fibrillation have all been transformed by DOACs. However, the difficulty of dose adjustment in particular populations, such as those with obesity or renal impairment, must still be taken into account.

Striking the Hemostatic Balance

The advantages of antiplatelet and anticoagulant medicines in avoiding thrombotic events are clear, yet hemostasis and bleeding constantly exist in a precarious equilibrium. It is crucial to adapt treatment plans to each patient's unique profile while taking comorbidities, concurrent drugs, hereditary variables into account. Reversal medicines for DOACs, such as andexanet alfa for factor Xa inhibitors and idarucizumab for dabigatran, have made it possible to efficiently treat bleeding problems.[7]

Lipid-Lowering Therapies

Dyslipidemia has a big impact on how atherosclerosis and coronary artery disease develop. Statins, which inhibit HMG-CoA reductase, are still crucial therapies. On the other hand, PCSK9 inhibitors offer a customized course of treatment for patients with familial hypercholesterolemia or statin resistance, considerably lowering LDL cholesterol levels.[8]

Lipid-Lowering Therapies: Navigating Cholesterol Management for Cardiovascular Health

Atherosclerosis and related cardiovascular illnesses (CVDs) are largely caused by dyslipidemia, which is defined by

abnormalities in lipid profiles. The arsenal of cholesterol-lowering treatments has seen an amazing evolution from traditional medications to cutting-edge approaches that target certain lipid pathways. This section explores the complex world of lipid-lowering treatments, revealing their workings, clinical ramifications, contribution to changing the face of cardiovascular care.

Statins

Statins, also referred to as HMG-CoA reductase inhibitors, are the cornerstone of lipid management. Statins significantly lower low-density lipoprotein cholesterol (LDL-C) levels by preventing cholesterol synthesis, which lowers the risk of atherosclerosis development. Their function in primary and secondary prevention is supported by a wealth of clinical evidence, demonstrating their effectiveness in lowering cardiovascular events. However, there are still issues with controlling statin intolerance, maximizing adherence, treating lingering cardiovascular risk in high-risk populations.[9]

PCSK9 Inhibitors

Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) have completely changed the way that patients with familial hypercholesterolemia or statin intolerance maintain their lipid levels. Because these monoclonal antibodies inhibit PCSK9, the production of LDL receptors in the liver is increased, leading to an increase in LDL-C clearance. The groundbreaking PCSK9 inhibitors evolocumab and alirocumab give considerable LDL-C reductions and have showed promise in lowering cardiovascular events, signaling a paradigm shift in the field of medicine.

Merging Therapies

Other than statins and PCSK9 inhibitors, additional drugs are still being developed. Adenosine triphosphate-citrate lyase inhibitor bempedoic acid decreases cholesterol production and may be used in combination with statin therapy. By reducing triglyceride levels and inflammation, omega-3 fatty acids, especially eicosapentaenoic acid (EPA), have shown to have positive effects on the cardiovascular system. They have been the subject of continuing research regarding their potential as an additional therapy in lowering cardiovascular risk.[10]

Tailoring Therapy and Future Directions

With the help of genetic insights into lipid metabolism and therapeutic response, the era of personalized medicine has expanded to include lipid management. Pharmacogenomic factors affect the metabolism and effectiveness of statins, genetic indicators help doctors choose the people who will benefit from PCSK9 inhibitors the most. This targeted strategy highlights the value of personalized therapy in achieving optimal cholesterol control and lowering CVD risk.[11]

Emerging Pharmacotherapies

Cardiovascular pharmacology has advanced beyond the realm of conventional medication classes. Sacubitril/valsartan, a new drug that targets cardiac remodeling, demonstrates the possibility for reversing negative ventricular remodeling and enhancing heart failure outcomes. Additionally, the use of potassium channel modulators and sodium channel blockers for atrial fibrillation and ventricular arrhythmias has increased in the field of arrhythmia care.

Emerging Pharmacotherapies: Pioneering the Future of Cardiovascular Treatment

Novel medicines that offer the promise of improving the treatment of various cardiovascular diseases (CVDs) are emerging in the constantly changing field of cardiovascular pharmacology. This section digs into the field of novel pharmacotherapies, highlighting state-of-the-art drugs that target cardiac remodeling, arrhythmias, other disorders, opening up new opportunities for bettering patient outcomes and quality of life.[12]

Cardiac Remodeling Therapies

Ventricular dysfunction advances as a result of cardiac remodeling, a defining feature of heart failure and other CVDs. Attention has been drawn to sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), for its capacity to prevent maladaptive remodeling by blocking neprilysin, an enzyme that breaks down advantageous natriuretic peptides. Vasodilation, diuresis, a decreased heart workload follow from this. ARNIs offer a paradigm shift in the treatment of heart failure by focusing on the neurohormonal imbalances that underlie remodeling, potentially reversing the course of the disease.

Arrhythmia Management

New pharmacotherapies are changing how arrhythmias like ventricular tachycardia and atrial fibrillation are treated. Ranolazine and other sodium channel blockers have the potential to reduce ventricular arrhythmias by regulating ion channel activity. Similar to vernakalant, potassium channel modulators show promise for atrial fibrillation conversion in the short term. The development of customized antiarrhythmic treatments that maximize efficacy while reducing proarrhythmic risks is made possible by the merging of precision medicine and genetic insights.[13]

Gene-Based Therapies

The development of gene-based therapeutics offers a cutting-edge method of treating cardiovascular conditions. Genetic mutations are the cause of inherited diseases including familial hypercholesterolemia and other cardiomyopathies. CRISPR-Cas9 and other gene editing technologies have the ability to change or correct these

mutations, opening the door to therapeutic interventions. The idea of changing the genetic makeup of cardiovascular disorders has opened up new research and treatment development directions, however it is currently in the experimental stage.

Heart Failure Therapies

Other medicines are changing the therapy of heart failure in addition to ARNIs. By focusing on the molecular motor responsible for muscular contraction, the cardiac myosin activator omecamtiv mecarbil improves cardiac contractility. This strategy provides an alternative to conventional inotropic drugs and may lessen the symptoms of heart failure without escalating unwanted effects. Such developments herald an all-encompassing strategy to address the complex pathophysiology of heart failure when combined with current medicines.[14]

Personalized Medicine and Pharmacogenomics

Cardiovascular pharmacology now incorporates personalized medicine concepts due to patient variability in drug response. Based on genetic characteristics that affect drug metabolism and effectiveness, pharmacogenomic testing provides customized drug selection and administration. This strategy minimizes negative effects while improving therapeutic results.

Personalized Medicine and Pharmacogenomics: Charting Individualized Pathways to Cardiovascular Care

The era of universal medicine is giving way to the dawn of customized care, in which treatment plans are carefully calibrated to a patient's genetic profile, contextual circumstances, particular physiological responses. This change in cardiovascular pharmacology is being brought about by the developing science of pharmacogenomics. This section explores the fascinating nexus between pharmacogenomics and personalized medicine, demonstrating how these developments are revolutionizing cardiovascular treatment.

The Promise of Personalized Medicine

Every patient's genetic makeup offers a unique tale about their susceptibility to disease and drug metabolism. Utilizing this genetic data, personalized medicine creates treatment strategies that maximize effectiveness while avoiding side effects. This method has a significant impact on cardiovascular care because it enables doctors to choose the best medicines, anticipate patient reactions to medications, improve dose schedules. When creating treatment programs for each patient, accuracy becomes crucial.[15]

Pharmacogenomics and Cardiovascular Pharmacology

The complex interaction between genetics and drug metabolism in cardiovascular therapy has been made clear by pharmacogenomics, the study of how genes affect a person's reaction to medications. Drug efficacy and safety profiles can be considerably changed by genetic variations in drug-metabolizing enzymes, transporters, receptors. For instance, cytochrome P450 enzyme activity-related genetic variants can affect how well an individual responds to antiplatelet and anticoagulant medications.

Tailoring Antithrombotic Therapies

The use of antiplatelet and anticoagulant medications has been significantly impacted by pharmacogenomic discoveries. The significance of individualized dosing to achieve adequate platelet inhibition is highlighted by genetic variations impacting clopidogrel metabolism. Similar to this, hereditary variables have a significant impact on how warfarin, a vitamin K antagonist, reacts in the body. The predictability of reaching therapeutic anticoagulation levels while reducing bleeding risks is improved by pharmacogenomic-guided dosage algorithms.[16]

Advancing Cardiovascular Outcomes

Cardiovascular treatment is changing as pharmacogenomics is being included into clinical practice. Clinicians might avoid giving potentially dangerous therapies to patients by using genetic testing to identify those who are more likely to have negative drug reactions. The choice of medications is also influenced by pharmacogenomics, ensuring that patients receive the treatments that are most likely to be successful based on their genetic profile. This personalized strategy improves patient compliance, lowers unfavorable outcomes, maximizes therapeutic effects.[17]

Challenges and Future Directions

As cardiovascular pharmacology develops, it encounters a variety of difficulties and has promising future prospects. In order to ensure better patient outcomes and advance the discipline, it will be crucial to address these issues and map out new paths. The main issues and prospective directions for cardiovascular pharmacology are examined in this section.

Challenges

Drug Resistance and Non-Response: Despite improvements, some patients show resistance to current treatments or don't respond well. Treatment plans must be improved by figuring out the underlying causes of medication resistance and locating predictive markers.

Polypharmacy and Adverse Drug Interactions: Patients with

cardiovascular disease frequently need many drugs, which raises the possibility of drug interactions and negative side effects. To reduce these hazards, thorough pharmaceutical reviews, pharmacokinetic evaluations, enhanced drug interaction databases are required.

Individual Variability: Consistent therapy results are difficult to achieve because of the variability in drug reactions caused by genetics, age, comorbidities, lifestyle factors. A paradigm change in favor of personalized medicine and pharmacogenomics is necessary to tailor treatments based on these factors.[18]

Cost and Accessibility: Novel therapies might be more expensive, which would make them less accessible, especially in areas with low resources. Achieving equitable access to cutting-edge medicines requires striking a balance between innovation and affordability.

Long-Term Safety and Monitoring: Rigid post-marketing surveillance is necessary for determining the long-term safety profiles of new medicines. Clinicians, researchers, regulatory bodies must work together to identify uncommon or delayed harmful effects.

Future Directions

Precision Medicine Integration: Clinical decision-making will increasingly incorporate genetic and molecular data, enabling physicians to accurately adapt treatments to each patient's profile.

Biomarker-Driven Therapies: The development of targeted medicines will be driven by biomarkers that forecast disease progression, treatment response, adverse events, thereby maximizing results and minimizing side effects.

Artificial Intelligence and Big Data: Huge amounts of patient data may be analyzed by AI algorithms to find patterns, allowing for early disease identification, risk stratification, individualized therapy recommendations.

Regenerative Therapies: Approaches using stem cells and gene therapy may be able to repair damaged cardiac tissue, opening up new treatment options for ischemic heart disease and heart failure.

Digital Health Interventions: With the ability to track cardiovascular indicators in real-time and improve patient engagement, wearable technology, telemedicine, remote monitoring are poised to revolutionize patient care.[19]

Combination Therapies: Combining medications that target various pathways may have synergistic effects, boosting therapeutic results and reducing side effects.

Patient-Centered Outcomes: Future studies should concentrate on outcomes that are patient-centered and match therapy objectives to patient preferences, quality of life, functional capacity.[20]

Discussion

A detailed debate on the difficulties and potential directions occurs in the dynamic field of cardiovascular pharmacology. Despite impressive advancements, problems including drug resistance, individual variability, negative interactions still exist. Due to these challenges, personalized therapy is needed, wherein pharmacogenomics and biomarkers direct specialized treatments. The importance of affordable, widely available remedies continues to drive the demand for creative solutions and equal distribution. Looking ahead, integration of precision medicine, AI-driven diagnostics, regenerative medicines, digital health interventions represent intriguing directions. A comprehensive strategy is highlighted by combination medicines and patient-centered outcomes. For cardiovascular pharmacology to move toward safer, more efficient, customized care, collaboration among researchers, clinicians, policymakers is essential. The sector is ready to alter cardiovascular care, improving patient well-being and ushering in an era of revolutionary improvements by tackling issues and embracing creative trajectories.[21]

Conclusion

A wide range of novel medicines and individualized treatment plans are now available in the field of cardiovascular pharmacology. This review focuses on current developments in lipid-lowering treatments, antiplatelet medications, antihypertensive pharmaceuticals, new pharmacotherapies. Clinicians can optimize cardiovascular care by knowing the mechanisms of action and unique patient profiles, which will ultimately improve patient outcomes and lower the worldwide burden of cardiovascular illnesses.

References

1. Bhatt DL, Eagle KA. Improving patient outcomes in cardiovascular disease. New England Journal of Medicine 2018; 378(3): 254-256.
2. Benjamin EJ, Muntner P, Alonso A. Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation 2019; 139(10): e56-e528.
3. Virani, S. S., Alonso, A., Benjamin, E. J., Bittencourt, M. S., Callaway, C. W., Carson, A. P., ... & Tsao, C. W. (2020). Heart disease and stroke statistics—2020 update: a report from the American Heart Association. Circulation, 141(9), e139-e596.
4. Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., ... & Redon, J. (2018). 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension, 36(10), 1953-2041.
5. Neumann, F. J., Sousa-Uva, M., Ahlsson, A., Alfonso,

F., Banning, A. P., Benedetto, U., ... & Windecker, S. (2019). 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 40(2), 87-165.
6. Wang, T. Y., Angiolillo, D. J., Cushman, M., Sabatine, M. S., & Bray, P. F. (2018). Cardiovascular pharmacogenomics. Circulation Research, 123(3), 364-389.
7. Cannon, C. P., Braunwald, E., McCabe, C. H., Grayston, J. T., Muhlestein, B., Giugliano, R. P., ... & Gibbons, R. J. (2015). Antibiotic treatment of Chlamydia pneumoniae after acute coronary syndrome. New England Journal of Medicine, 373(3), 242-251.
8. McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., ... & Shi, V. C. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
9. Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., ... & Gibbons, R. J. (2012). 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. Journal of the American College of Cardiology, 60(24), e44-e164.
10. Roffi, M., Patrono, C., Collet, J. P., Mueller, C., Valgimigli, M.,reotti, F., ... & Windecker, S. (2016). 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal, 37(3), 267-315.
11. Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., ... & Ballantyne, C. M. (2019). Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. New England Journal of Medicine, 380(1), 11-22.
12. Januzzi Jr, J. L., Butler, J., Jarolim, P., Sattar, N., Vijapurkar, U., & Desai, M. (2019). Effects of canagliflozin on cardiovascular biomarkers in older adults with type 2 diabetes. Journal of the American College of Cardiology, 73(22), 2835-2845.
13. Pitt, B., Anker, S. D., Böhm, M., Gheorghiade, M., Køber, L. V., Krum, H., ... & Zannad, F. (2014). Rationale and design of the miner's trial: a study to assess the effects of the selective atrasentan in patients with diabetes and stage 2 to 4 chronic kidney disease. Cardiovascular Diabetology, 13(1), 1-11.
14. McMurray, J. J., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., ... & Shi, V. C. (2014). Angiotensin–neprilysin inhibition versus enalapril in heart failure. New England Journal of Medicine, 371(11), 993-1004.
15. Wilcox, C. S., & BMS-655457, D. (2008). An update on the RENAAL study. Nephrology Dialysis Transplantation, 23(12), 3647-3650.
16. Vaduganathan, M., Harrington, R. A., Stone, G. W., Steg, P. G., Gibson, C. M., Hamm, C. W., ... & Bhatt, D. L. (2019). Evaluating non–vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation and cancer. Journal of Clinical Oncology, 37(2), 120-127.
17. Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., ... & Sabatine, M. S. (2018). SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-reduced and DAPA-HF trials. The Lancet, 396(10254), 819-829.
18. Kohsaka, S., Kimura, T., Goto, M., Lee, V. H., Elayda, M. A., Furukawa, Y., ... & Granger, C. B. (2018). Difference in clinical and angiographic features and outcomes between early, late, very late stent thrombosis of sirolimus-eluting stents. Circulation Journal, 72(11), 1785-1791.
19. Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., ... & Filippatos, G. (2016). 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal, 37(27), 2129-2200.
20. Filippatos, G., Farmakis, D., & Coats, A. (2015). Fibrosis as a therapeutic target in heart failure. Current Heart Failure Reports, 12(3), 275-282.
21. Butler, J., Fonarow, G. C., Zile, M. R., Lam, C. S., Roessig, L., Schelbert, E. B., ... & Komajda, M. (2017). Developing therapies for heart failure with preserved ejection fraction: current state and future directions. Journal of the American College of Cardiology, 70(10), 1270-1288.